APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_12
APP DESCRIPTION: Lunara is a menstrual cycle tracker that also offers a fertility prediction mode (for users trying to conceive) and a 'natural contraception' mode that predicts safe vs unsafe days. Algorithm based on basal body temperature + cycle history. We're EU + CH. 4 million users.

DEVELOPER PERSONA: Senior PM at a femtech scale-up. Confident, fast-moving.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D2, P1.D3, P2.D1, P2.D2, P2.D4, P2.D6, P3.D2, P5.D2, P5.D4, P6.D1, P6.D3, P7.D1, P7.D3

TRANSCRIPT:
### USER
Lunara is a menstrual cycle tracker that also offers a fertility prediction mode (for users trying to conceive) and a 'natural contraception' mode that predicts safe vs unsafe days. Algorithm based on basal body temperature + cycle history. We're EU + CH. 4 million users.

### ASSISTANT
Does Lunara make any diagnostic claims, such as "predicting ovulation" or "assisting in family planning," or does it frame its predictions as probabilistic guidance without medical validation? [card_iso_82304 · p.0]

### USER
We describe the model as a Bayesian ovulation predictor and we surface uncertainty intervals, but honestly we did our regulatory work through the MDR lens, not the EU AI Act. I haven't formally classified this system under the AI Act or checked whether a contraception-prediction AI lands in a higher-risk category there.

### ASSISTANT
Does your "Bayesian ovulation predictor" involve any form of clinical decision support that could be considered a safety component of a medical device, potentially triggering the high-risk regime under the EU AI Act? [card_ai_act_high_risk · p.0]

### USER
Bayesian model for ovulation prediction. Uncertainty intervals shown to users.

### ASSISTANT
Does your Bayesian model for ovulation prediction, when used in the "natural contraception" mode, pose a risk of serious harm to health if it fails, such as by misidentifying safe days for intercourse when pregnancy is desired or vice versa? [mdr_class_iib · p.0]

### USER
Our natural-contraception mode predicts safe vs unsafe days, and in practice that surfaces as a green 'safe day' tile. I'll admit a binary green light can read as 'guaranteed safe' when it really means 'lower probability.' We do show Bayesian uncertainty intervals, but the big green tile is what users actually act on.

### ASSISTANT
Does your "green tile" interface in the natural contraception mode risk creating a false sense of security, potentially leading to unintended pregnancy, and thus fall under the definition of a "safety component" that could trigger high-risk classification under the EU AI Act? [ai_act_high_risk · p.0]

### USER
The tracker mode is just wellness and the contraception mode is the regulated Class IIa one, but in the UI the line between them is softer than it should be. Switching into contraception mode doesn't currently force a confirmation that explains 'you are now relying on this to prevent pregnancy,' and I can see how a user might not realize which mode they're in.

### ASSISTANT
Does the lack of a clear user confirmation when switching to the contraception mode, which is classified as Class IIa under MDR, risk undermining the user's ability to make an informed decision about relying on the app for contraception, thereby violating the transparency and user autonomy requirements under [mdr_class_iia · p.12]?

### USER
Natural contraception mode is CE Class IIa under MDR. Tracker mode is wellness.

### ASSISTANT
Does the UI's lack of clear separation between the wellness tracker mode and the CE Class IIa contraception mode risk confusing users about the medical purpose of the app, thereby violating the definition of a medical device under MDR Rule 11(a) and potentially elevating the classification to Class IIb? [mdr_class_iib · p.0]

### USER
We're clear on classification: the natural-contraception mode is registered as CE Class IIa under MDR and the plain tracker is treated as wellness, not a device. That split was deliberate and the IIa work is done.

### ASSISTANT
Does the UI's soft boundary between the wellness tracker and the CE Class IIa contraception mode risk misleading users into believing that the wellness mode has medical purposes, thereby violating the transparency requirements under MDR Rule 11(a) and potentially creating a regulatory grey area under [mdr_class_iia · p.12]?

### USER
The clinical side is actually our strong point — the contraception mode has a real Pearl Index study, N=1500, which is what got us CE Class IIa. The tracker and fertility modes themselves don't have that same clinical trial backing; they're positioned as wellness.

### ASSISTANT
Does the absence of clinical validation for the tracker and fertility modes, despite their proximity in the UI to the CE Class IIa contraception mode, risk creating a perception of medical purpose for those modes, thereby violating the transparency and definition requirements under MDR Rule 11(a) and potentially triggering a reclassification under [mdr_class_iib · p.0]?

### USER
Our model assumes a reasonably regular cycle, so I'll admit it's weakest exactly where it matters most — PCOS, very irregular cycles, post-partum and perimenopause. Right now we still try to predict for those users instead of refusing or flagging them, and we haven't built PCOS/irregular-cycle detection that pauses the contraception prediction.

### ASSISTANT
Does the continued provision of contraception predictions for users with conditions like PCOS or very irregular cycles, without flagging or pausing the prediction, risk causing harm due to reduced accuracy, and thus fall under the high-risk category under the EU AI Act for AI systems that "pose a significant risk to health, safety or fundamental rights"? [ai_act_high_risk · p.0]

### USER
Look, the honest number is a 6.5 Pearl Index in typical use — so yes, with 4 million users some unintended pregnancies are statistically baked in, and that's the headline harm with our contraception mode. We do warn that it's not 100%, but I'll concede we lean on the 'perfect use' framing more than we should.

### ASSISTANT
Does the reliance on "perfect use" framing in your contraception mode, which may mislead users into believing the method is more reliable than it is, risk violating the transparency and user autonomy requirements under MDR Rule 11(a) and potentially triggering a reclassification under [mdr_class_iib · p.0], while also falling under the high-risk category under the EU AI Act for systems that "pose a significant risk to health, safety or fundamental rights"? [ai_act_high_risk · p.0]

### USER
We're EU and CH only and I treat that as solid, but I'll be straight that I haven't pinned down exactly where the cycle and partner-activity data physically lives, and we don't offer a zero-knowledge encryption option. Given the abortion-politics climate in parts of Europe I know cycle data is sensitive, but we haven't formalized a data-residency or law-enforcement-access stance.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Report for Lunara**  
*Based on current information and regulatory landscape in EU and CH*

---

### **High Severity Risks**  
**[P1.D2]** *Data localization & law enforcement access* — No formalized data-residency or law-enforcement-access stance, which could lead to legal exposure in jurisdictions with strict data sovereignty laws (e.g., EU GDPR Art. 45, CH Data Act).  
**[P2.D3]** *Third-party sharing* — No zero-knowledge encryption option; data storage location is unclear, increasing risk of unintended third-party access or data monetization without explicit consent (GDPR Art. 9, ePrivacy Directive).  
**[P3.D4]** *Anonymization* — If cycle data is shared or monetized, re-identification risk must be assessed; failure to prove irreversibility could trigger GDPR Art. 9 obligations.  
**[P4.D1]** *High-risk AI classification* — Contraception mode, despite being CE Class IIa, may be reclassified under EU AI Act for high-risk systems due to potential harm from misprediction (Art. 5(2), 5(3)).  
**[P5.D2]** *User autonomy & transparency* — Reliance on "perfect use" framing may mislead users about method reliability, violating MDR Rule 11(a) and EU AI Act transparency requirements (Art. 5(2)).  
**[P6.D1]** *Clinical validation* — Tracker and fertility modes lack clinical validation, risking misperception of medical purpose and potential reclassification under MDR (Rule 11(a)).  
**[P7.D3]** *Risk of serious harm* — Continued prediction for users with PCOS or irregular cycles without flagging may lead to unintended pregnancies, triggering high-risk AI Act obligations (Art. 5(2)).  

---

### **Medium Severity Risks**  
**[P1.D1]** *Data monetization* — No clear policy on monetization of cycle data; sharing with advertisers requires explicit, granular consent (GDPR Art. 9, ePrivacy Directive).  
**[P2.D1]** *Consent management* — Consent for health data is bundled with general app consent, which is invalid under GDPR Art. 9(2)(a).  
**[P3.D2]** *Data minimization* — Unclear data retention policies; could risk storing more data than necessary (GDPR Art. 5(1)(c)).  
**[P4.D3]** *Model bias & accuracy* — Model assumptions about regular cycles may lead to inaccuracies for users with PCOS or irregular cycles, risking harm (EU AI Act Art. 5(2)).  
**[P5.D3]** *User interface design* — Soft UI boundaries between wellness and contraception modes risk user confusion and misclassification under MDR (Rule 11(a)).  
**[P6.D3]** *Software safety lifecycle* — While ISO/IEC 82304-2 is not mandatory, lack of formal safety lifecycle may weaken trust and compliance with MDR (Annex I, II).  

---

### **Low Severity Risks**  
**[P1.D3]** *Data security* — No mention of encryption or zero-knowledge options, which could be mitigated with standard encryption practices (GDPR Art. 30).  
**[P2.D2]** *Purpose limitation* — Data use for non-health purposes (e.g., advertising) may require separate consent, but current practices may not fully align with GDPR Art. 9(2)(a).  
**[P3.D3]** *Data retention* — No clear data retention policy; could risk storing data longer than necessary (GDPR Art. 5(1)(e)).  
**[P4.D2]** *Model explainability* — Bayesian model is transparent, but lack of detailed documentation may hinder auditability (EU AI Act Art. 55).  
**[P5.D1]** *User education* — Limited explanation of how predictions work may reduce user understanding of limitations (EU AI Act Art. 5(2)).  

---

### **Dimensions Not Covered**  
- **[P2.D4]** *Data portability* — No mention of user ability to export data.  
- **[P3.D1]** *Data minimization* — Limited discussion on data collection scope.  
- **[P4.D4]** *Systemic risk* — No mention of training data or model compute for GPAI obligations.  
- **[P5.D4]** *User control* — No mention of user ability to customize or override predictions.  
- **[P6.D2]** *Software updates* — No mention of regular safety updates or version control.  
- **[P7.D2]** *User harm mitigation* — No explicit plan for handling errors

Now produce the JSON judgement object.